Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

Core Insights - Taysha Gene Therapies, Inc. reported a quarterly loss of $0.09 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, marking an earnings surprise of -28.57% [1] - The company generated revenues of $1.99 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 15.73% and showing significant growth from $1.11 million a year ago [2] - Taysha Gene Therapies shares have increased approximately 59.5% year-to-date, outperforming the S&P 500's gain of 8.4% [3] Financial Performance - Over the last four quarters, Taysha Gene Therapies has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $1.73 million, and for the current fiscal year, it is -$0.31 on revenues of $7.51 million [7] Industry Context - The Medical - Generic Drugs industry, to which Taysha Gene Therapies belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]